Cisplatin is a potent and effective chemotherapeutic agent used to treat various tumors of the head, neck, ovary, testis, and bladder. However, it is also highly nephrotoxic and has the potential to cause renal failure in up to 10% of patients. The cisplatin-induced kidney model is used to examine the ability of novel compounds to attenuate or reverse renal damage caused by cisplatin treatment.
Preclinical Drug Efficacy Studies
Animals receive an i.p. dose of 10mg/kg cisplatin which produces a toxic effect within 3-days of administration. 72-hours later, animals are sacrificed and blood is collected for assay of blood urea nitrogen and serum creatinine. Administration of compounds will follow the schedule set-forth within the study protocol.
Clinical observations, body weight, assay of serum creatinine and blood urea nitrogen to determine renal function
Taguchi T, Nazreen MR, Abid and MS Razzouque. (2005) Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol; 148: 107-21.
Li S, Gokden N, Okusa MD, Bhatt R, Portilla D. (2005) Anti-inflammatory effect of fibrate protects from cisplatin induced ARF. Am J Physiol Renal Physiol; 289: F469-80. (2005)